Radioimmunoassay Market Size, Share & Industry Analysis, By Product Type (Kits and Reagents and Instruments), By Application (Endocrinology, Oncology, Cardiology, Infectious Diseases, Allergy and Autoimmune Disorders, and Others), By End-user (Standalone Clinical Diagnostics Laboratories, Hospital Laboratories, Pharmaceutical and Biotechnology Companies, and Others), and Regional Forecast, 2025-2032

The global radioimmunoassay market size was valued at USD 211.7 million in 2024. The market is expected to grow from USD 218.3 million in 2025 to USD 264.0 million by 2032, exhibiting a CAGR of 2.8% during the forecast period.

Radioimmunoassay (RIA) is a highly sensitive laboratory technique used to measure minute concentrations of biological substances, such as hormones, drugs, vitamins, or antigens, in samples such as blood, serum, plasma, or urine. It’s based on the principle of antigen–antibody binding and the use of a radioactively labeled substance to quantify the concentration of the analyte.

From Revvity, Inc. and DIAsource to MP Biomedicals, Danaher Corporation, and DiaSorin, key industry players are sharpening their focus on R&D activities, rolling out advanced technologies and novel platforms. Their efforts are setting the stage for strong global market growth.

As tech innovation accelerates and personalized medicine takes center stage, the market future looks promising. Challenges do exist, tough regulations and strong competition among them, but the steady flow of new ideas and collaborative strategies keeps the industry moving toward a more streamlined and widely accessible healthcare environment.

Market Dynamics

Market Drivers

Rise In Endocrine and Oncological Disorders to Support Market Growth

The growing prevalence of endocrine and cancer-related disorders continues to drive demand for radioimmunoassay, a trusted technique known for its remarkable sensitivity and accuracy. Hormone tests for analytes such as insulin, cortisol, and thyroid hormones (T3, T4, and TSH) still rely heavily on this method, especially in specialized and reference laboratories. At the same time, the expansion of biologics research and bioanalytical testing has further strengthened the role of radioimmunoassay in receptor-binding and tracer studies.

Rapid improvements in diagnostic infrastructure across countries such as China, India, and Brazil have also fueled reagent demand. In many of these settings, radioimmunoassay remains a practical and cost-effective option, particularly where advanced chemiluminescent systems are not yet widely available. Its ability to detect analytes at extremely low concentrations—down to the picogram level—makes it particularly valuable for niche research applications focused on low-abundance biomarkers. Despite the industry’s gradual move toward automated platforms such as CLIA and ELISA, the precision, reliability, and affordability of radioimmunoassay reagents are likely to sustain their market presence well into 2032.

Market Restraints

Stringent Radiation Regulation & Technological Shift to Restrict Market Growth

Stringent regulations on handling radioactive materials, managing waste, and maintaining licensed laboratories have slowed the growth of radioimmunoassay in developed markets. Agencies such as the U.S. Nuclear Regulatory Commission (NRC) and the European Atomic Energy Community (EURATOM) enforce extensive compliance standards, which significantly increase the operational burden on diagnostic facilities. The need for specialized storage, trained staff, and careful management of short-lived isotopes often discourages the establishment of new RIA setups.

At the same time, the industry’s gradual shift toward non-radioactive techniques, such as chemiluminescent (CLIA) and enzyme-linked immunoassays (ELISA), has accelerated the replacement of RIA in routine diagnostics. Major companies, including Siemens Healthineers, Abbott, and Roche Diagnostics, have already shifted to automated CLIA platforms that offer safer operations and higher efficiency. These transitions, combined with strict regulatory barriers, are expected to limit the radioimmunoassay market growth in the coming years.

Market Opportunities

Rise in Research and Development Spending and Academic Research Funding to Open New Market Growth Avenues

Emerging economies and the global expansion of biopharmaceutical research are opening new growth avenues for the market. Rising pharmaceutical R&D investments have expanded the application of RIA in pharmacokinetic and ligand-binding studies, where precise and highly sensitive analysis is crucial.

• According to several credible sources, global pharmaceutical R&D spending was nearly USD 288 billion in 2024, a 1.5% increase from 2023.

Companies such as DIAsource and the Institute of Isotopes are capitalizing on this demand by introducing multianalyte RIA panels and low-volume kits designed for contract research organizations and academic laboratories. In countries such as India and China, growing research funding and relatively lenient isotope-use regulations are driving new orders for gamma counters and radiolabeled reagents.

There is also renewed interest in applying RIA to veterinary endocrinology and toxicology testing, where affordability and reproducibility are valued more than automation. Meanwhile, the relocation of reagent manufacturing to Eastern Europe and Asia has helped lower isotope supply costs and shorten delivery times. Although radioimmunoassay is a well-established technology, regional manufacturing and research-driven applications are expected to continue creating promising niche opportunities for market players in the coming years.

Market Challenges

Niche Demand and Several Structural Challenges Hinders Radioimmunoassay Scalability

Although radioimmunoassay continues to serve a niche segment, several structural barriers limit its broader growth potential. A key issue lies in the fragile supply chain for isotopes such as I-125 and Co-57, where even minor disruptions can halt reagent production and distribution. For instance, the Iodine-125 shortage in Europe in 2022 led to visible delays in kit availability. Compounding this challenge is the shrinking pool of skilled professionals trained in traditional RIA procedures, as most laboratory staff now specialize in chemiluminescent or molecular platforms.

In advanced markets, reimbursement inconsistencies also weigh on adoption. Many insurers prioritize non-radioactive testing alternatives, making RIA financially less attractive. After the COVID-19 pandemic, numerous hospitals permanently decommissioned RIA facilities due to high waste disposal costs and lower testing volumes.

In developing regions, the demand for RIA reagents is growing; however, the lack of nuclear waste management infrastructure and dependence on imported isotopes create significant operational risks. Frequent licensing renewals, regulatory inspections, and sourcing challenges further add to the cost burden. While RIA continues to play a vital role in certain research and diagnostic areas, its long-term viability depends on resolving these workforce, infrastructure, and compliance challenges.

Radioimmunoassay Market Trends

Decentralization & Innovative Technology Adaptation is Transforming RIA Platforms

In recent years, radioimmunoassay systems have undergone steady modernization through miniaturization and digital upgrades. Leading manufacturers such as Revvity, Beckman Coulter, and Izotop are introducing automated gamma counters equipped with software for precise dose calibration and advanced quality control, helping to update and extend the life of older laboratory setups.

A notable trend shaping the market is the regional localization of manufacturing, particularly in the Asia Pacific and Eastern Europe regions. This shift helps reduce the high costs associated with importing and transporting isotopes. For example, the Beijing North Institute of Biological Technology (BNIBT) expanded its domestic RIA kit production in 2023 to meet the growing demand for endocrinology testing within China.

Another development involves hybrid testing workflows that pair RIA with ELISA or CLIA confirmation steps to improve result accuracy in complex research applications. At the same time, the use of radiation-safe consumables and disposable shielding materials is addressing stricter safety and regulatory expectations.

Digitalization is also transforming the field, with many laboratories adopting cloud-based systems for storing RIA data and automating dose normalization. These advances are enhancing reproducibility and data integrity. Together, such innovations are shifting radioimmunoassay from a traditional manual procedure into a semi-automated, digitally enabled tool tailored for modern research environments.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type

Kits and Reagents Led Market Due to Frequent Test Volume in Healthcare Settings

Based on product type, the market is divided into kits and reagents and instruments.

The kits and reagents segment dominated the market in 2024, owing to emerging regions' dependence on consumables due to slower instrument replacement. Additionally, kits and reagents are dominant due to the high frequency of testing in healthcare settings.

The instrument segment is expected to grow at a CAGR of 2.1% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Endocrinology Dominated Market Due to Rising Prevalence of Endocrine Disorders

Based on application, the market is segmented into endocrinology, oncology, cardiology, infectious diseases, allergy and autoimmune disorders, and others.

The endocrinology segment dominated the market in 2024, driven by the growing prevalence of endocrine disorders among the global and U.S. patient population. Diabetes is the most prevalent endocrine disorder worldwide and in the U.S., followed by thyroid disorders and metabolic syndrome. Additionally, in 2025, the segment is expected to account for a 44.3% share of the market.

• For instance, according to the 2024 statistics published by the International Diabetes Federation (IDF), globally, an estimated 589 million adults have diabetes, with that number projected to reach USD 853 million by 2050.

The allergy and autoimmune disorders segment is set to flourish with a growth rate of 3.3% over the forecast period.

By End-user

Higher Test Volume Boosted Adoption of Radioimmunoassay at Standalone Clinical Diagnostics Laboratories

Based on end-user, the market is segmented into standalone clinical diagnostics laboratories, hospital laboratories, pharmaceutical and biotechnology companies, and others.

The standalone clinical diagnostics laboratories segment dominated the market in 2024, driven by the increasing number of these laboratories, which in turn supports the growing number of diagnostic procedures among patients. Additionally, the outsourcing of clinical diagnostic services by public hospitals to standalone clinical laboratories is a significant factor contributing to the high volume of tests performed in these settings. Furthermore, the segment is set to hold a 34.5% share in 2025.

• For instance, according to data published by the American Clinical Laboratory Association in 2023, there are approximately 322,488 clinical laboratories in the U.S.

In addition, the pharmaceutical and biotechnology companies segment is projected to grow at a CAGR of 3.2% during the study period.

Radioimmunoassay Market Regional Outlook

By geography, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2023, valued at USD 63.2 million, and also took the leading share in 2024 with USD 64.7 million. Some of the prominent factors contributing to the region’s dominance include the presence of major companies, such as Revvity, Inc., MP Biomedicals, and Danaher Corporation, especially in the U.S. Favorable government regulations, a well-established diagnostic infrastructure, and the adoption of technologically advanced diagnostic techniques are fueling market expansion in the region.

In 2025, the U.S. market is estimated to reach USD 60.0 million. The increasing prevalence of chronic and infectious diseases in the U.S. is one of the factors driving the market growth. This, along with the growing presence of a well-established healthcare infrastructure, a favorable reimbursement scenario for radioimmunoassay diagnostic tests, and higher awareness among the patient population about primary diagnosis, is leading to the higher adoption of advanced instruments and tests by healthcare settings in the country.

Europe

Europe is set to register a CAGR of 2.6% and reach a valuation of USD 60.1 million by 2025. The growth is attributed to several factors, including well-established healthcare infrastructures, increased healthcare expenditure, and a rising prevalence of chronic endocrine disorders, cancer, and other diseases. Backed by these factors, countries including the U.K. are expected to record valuations of USD 8.6 million, Germany to record USD 12.8 million, and France to record USD 9.4 million in 2025.

Asia Pacific

The market in Asia Pacific is estimated to reach USD 57.9 million by 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 11.2 million and USD 14.7 million, respectively, in 2025.

Latin America

Latin America is expected to reach USD 19.5 million in 2025. The growing geriatric population, along with the increasing prevalence of several disorders, further drives usage in these regions.

Middle East & Africa

In the Middle East & Africa, the GCC is set to reach a value of USD 6.7 million by 2025.

Competitive Landscape

Key Industry Players

Top Participants Emphasize R&D Efforts to Maintain Their Dominance

The global market is semi-consolidated. A few prominent players, such as Revvity, Inc., DIAsource, MP Biomedicals, Institute of Isotopes, and DiaSorin S.p.A., hold a majority share of the global market. The increasing focus of companies on R&D activities to develop and introduce technologically advanced products and novel systems is a significant factor contributing to the growing share of these companies.

Other market players include Danaher Corporation, Biosigma S.p.A., Tecan Group Ltd., and several small-scale companies. These players are concentrating on launching new products, expanding their geographic presence, and establishing a strong brand presence, further supporting the global radioimmunoassay market share.

LIST OF KEY RADIOIMMUNOASSAY COMPANIES PROFILED

• Revvity, Inc. (U.S.)
• DIAsource (Belgium)
• MP Biomedicals (U.S.)
• Danaher Corporation (U.S.)
• DiaSorin S.p.A. (Italy)
• Shenzhen New Industry Biomedical Engineering Co., Ltd. (China)
• Institute of Isotopes (Hungary)
• Biosigma S.p.A. (Italy)
• Tecan Group Ltd. (Switzerland)
• Beijing Chemclin Biotech Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENTS

• October 2025 – ARCHIMED Diagnostics acquired ARK Diagnostics, a global leader in disease and drug monitoring & detection.
• September 2025 - BioVendor Group, a leading European innovator in immunodiagnostics and molecular diagnostics, announced a strategic transformation of its organizational structure and a unified presentation under the BioVendor Group brand. It is structured into three global strategic divisions: Immunodiagnostics, Molecular Diagnostics, and Radio-immunodiagnostics.
• January 2025 – Medipan GmbH announced an extension of the shelf life for its radioimmunoassay (RIA) kits, specifically the SELco TSH Rapid, SELco Tg 1-Step, and SELco Calcitonin kits.
• May 2023 – Revvity, Inc. officially launched as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.
• December 2022 – Medipan GmbH introduced the SELco TRAb human 1 step, a sensitive radioimmunoassay (RIA) designed for the detection of thyroid-stimulating hormone receptor antibodies (TRAb).

REPORT COVERAGE

The global radioimmunoassay market analysis provides an in-depth study of market size & forecast by all the market segments included in the report. It includes details on market dynamics and trends expected to drive the market during the forecast period. It offers information on the technological advancements, new product launches, key industry developments, and details on partnerships, mergers & acquisitions. The market research report also encompasses a detailed competitive landscape, including information on market share and profiles of key operating players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation